Pharmacologic options available to treat symptomatic intradialytic hypotension.

M A Perazella

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;38(4 Suppl 4):S26-36

PMID: 11602458

Full Text on Elsevier Science View on PubMed

Abstract

Treatment of symptomatic intradialytic hypotension (IDH) is a difficult task for the practicing nephrologist. Minimizing patient factors that precipitate IDH as well as dialysis procedure-related components that lower blood pressure are the initial approaches to this problem. However, despite these maneuvers, hypotension often persists in a group of high-risk patients. Pharmacologic interventions are often used to reduce IDH. Unfortunately, many of the available therapies are marginally effective and/or poorly tolerated. A few therapies appear to be efficacious and well tolerated-carnitine, sertraline, and midodrine. This article reviews the various pharmacologic therapies used for IDH and makes recommendations for treatment of this difficult problem.

Address: Section of Nephrology, Yale University School of Medicine, New Haven, CT 06520-8029, USA. [email protected]

DOI: 10.1053/ajkd.2001.28092

Link outs

Free resources

Medical:

https://medlineplus.gov/lowbloodpressure.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0272...

MeSH Terms: Adrenergic Agents, Autonomic Nervous System, Caffeine, Carnitine, Ephedrine, Fludrocortisone, Hemodiafiltration, Humans, Hypertrophy, Left Ventricular, Hypotension, Kidney Failure, Chronic, Midodrine, Renal Dialysis, Risk Factors, Selective Serotonin Reuptake Inhibitors, Sertraline